WO2009063215A3 - Use of crth2 antagonist compounds - Google Patents

Use of crth2 antagonist compounds Download PDF

Info

Publication number
WO2009063215A3
WO2009063215A3 PCT/GB2008/003843 GB2008003843W WO2009063215A3 WO 2009063215 A3 WO2009063215 A3 WO 2009063215A3 GB 2008003843 W GB2008003843 W GB 2008003843W WO 2009063215 A3 WO2009063215 A3 WO 2009063215A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist compounds
crth2 antagonist
allergic
compounds
crth2
Prior art date
Application number
PCT/GB2008/003843
Other languages
French (fr)
Other versions
WO2009063215A2 (en
Inventor
Michael George Hunter
Eric Roy Pettipher
Colin Michael Perkins
Mark Anthony Payton
Luzheng Xue
Original Assignee
Oxagen Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Limited filed Critical Oxagen Limited
Publication of WO2009063215A2 publication Critical patent/WO2009063215A2/en
Publication of WO2009063215A3 publication Critical patent/WO2009063215A3/en
Priority to US12/779,638 priority Critical patent/US20110124683A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compounds of general formula (I): wherein R1, R2, R3, R4 and R5 are as defined herein for desensitising the immune system of a subject to allergens, thus preventing or reducing the symptoms of allergic conditions such as allergic asthma, allergic rhinitis or atopic dermatitis.
PCT/GB2008/003843 2007-11-13 2008-11-13 Use of crth2 antagonist compounds WO2009063215A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/779,638 US20110124683A1 (en) 2007-11-13 2010-05-13 Use of CRTH2 Antagonist Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0722216.9A GB0722216D0 (en) 2007-11-13 2007-11-13 Use of crth2 antagonist compounds
GB0722216.9 2007-11-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/003824 Continuation-In-Part WO2009063202A2 (en) 2007-11-13 2008-11-13 Use of crth2 antagonist compounds

Publications (2)

Publication Number Publication Date
WO2009063215A2 WO2009063215A2 (en) 2009-05-22
WO2009063215A3 true WO2009063215A3 (en) 2009-08-27

Family

ID=38896181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/003843 WO2009063215A2 (en) 2007-11-13 2008-11-13 Use of crth2 antagonist compounds

Country Status (2)

Country Link
GB (1) GB0722216D0 (en)
WO (1) WO2009063215A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EA018901B1 (en) 2008-02-01 2013-11-29 ПАНМИРА ФАРМАСЬЮТИКАЛС, ЭлЭлСи N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin dreceptors
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
EP2268611A2 (en) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
US8501959B2 (en) 2008-06-24 2013-08-06 Panmira Pharmaceuticals, Llc Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
US20110190227A1 (en) 2008-07-03 2011-08-04 Amira Pharmaceuticals, Inc. Antagonists of Prostaglandin D2 Receptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
WO2010142934A1 (en) * 2009-06-12 2010-12-16 Pulmagen Therapeutics (Asthma) Limited Indole derivatives as ligands of crth2 receptors
CA2768492A1 (en) 2009-07-31 2011-02-03 Panmira Pharmaceuticals, Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
SG178252A1 (en) 2009-08-05 2012-03-29 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
EA201270653A1 (en) 2010-01-06 2012-11-30 ПАНМИРА ФАРМАСЬЮТИКАЛС, ЭлЭлСи ANTAGONIST DPI ITS APPLICATION
SI2558447T1 (en) 2010-03-22 2015-01-30 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
EP2697223B1 (en) 2011-04-14 2016-07-13 Actelion Pharmaceuticals Ltd. 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
WO2013088109A1 (en) * 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
AR099767A1 (en) 2014-03-17 2016-08-17 Actelion Pharmaceuticals Ltd DERIVATIVES OF ACETIC ACID AZAINDOL AND ITS USE AS MODULATORS OF THE PROSTAGLANDINA D2 RECEPTOR
CN106103437A (en) 2014-03-18 2016-11-09 埃科特莱茵药品有限公司 Azaindole acetogenin and the purposes as prostaglandin D 2 receptor regulator thereof
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI711616B (en) 2015-09-15 2020-12-01 瑞士商愛杜西亞製藥有限公司 Crystalline forms
WO2017104728A1 (en) * 2015-12-16 2017-06-22 国立大学法人東京大学 Medicine for treating food allergy
JP7044754B2 (en) * 2016-07-21 2022-03-30 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Indole derivative as a CRTH2 inhibitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044260A1 (en) * 2003-10-23 2005-05-19 Oxagen Limited Use of crth2 antagonist compounds in therapy
WO2006092579A1 (en) * 2005-03-01 2006-09-08 Oxagen Limited Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid
WO2006095183A1 (en) * 2005-03-11 2006-09-14 Oxagen Limited 1-acetic acid-indole derivatives with pgd2 antagonist activity
WO2007107772A1 (en) * 2006-03-22 2007-09-27 Oxagen Limited Salts with crth2 antagonist activity
WO2008012511A1 (en) * 2006-07-22 2008-01-31 Oxagen Limited Compounds having crth2 antagonist activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044260A1 (en) * 2003-10-23 2005-05-19 Oxagen Limited Use of crth2 antagonist compounds in therapy
WO2006092579A1 (en) * 2005-03-01 2006-09-08 Oxagen Limited Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid
WO2006095183A1 (en) * 2005-03-11 2006-09-14 Oxagen Limited 1-acetic acid-indole derivatives with pgd2 antagonist activity
WO2007107772A1 (en) * 2006-03-22 2007-09-27 Oxagen Limited Salts with crth2 antagonist activity
WO2008012511A1 (en) * 2006-07-22 2008-01-31 Oxagen Limited Compounds having crth2 antagonist activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "View of NCT00290381 on 2006_02_10", CLINICALTRIALS.GOV ARCHIVE, 10 February 2006 (2006-02-10), XP002535100, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00290381/2006_02_10> *
ANONYMOUS: "View of NCT00697281 on 2008_06_12", CLINICALTRIALS.GOV ARCHIVE, 12 June 2008 (2008-06-12), XP002535101, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00697281/2008_06_12> *

Also Published As

Publication number Publication date
GB0722216D0 (en) 2007-12-27
WO2009063215A2 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
WO2009063215A3 (en) Use of crth2 antagonist compounds
WO2007146838A3 (en) Substituted phenyl acetic acids as dp-2 antagonists
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
WO2007143745A3 (en) Substituted phenyl acetic acids as dp-2 antagonists
WO2009080638A3 (en) Sulfamides as zap-70 inhibitors
WO2010031184A8 (en) Azaindole derivatives as crth2 receptor antagonists
WO2010142766A3 (en) Pyrimidine derivatives as zap-70 inhibitors
NZ594854A (en) Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
WO2009043889A3 (en) Oxadiazole derivatives
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
UA99524C2 (en) Triazole derivatives useful for the treatment of diseases
WO2010079431A3 (en) Compounds for the prevention and treatment of cardiovascular disease
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2011112766A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2009156462A3 (en) Organic compounds
WO2010030813A3 (en) Methods for inhibiting ocular angiogenesis
EP2185514A4 (en) Vinyl-aryl derivatives for inflammation and immune-related uses
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2010115751A3 (en) Oxadiazole derivatives
WO2011056511A3 (en) 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
WO2009021965A3 (en) Substituted quinoline derivatives as h1 receptor antagonists
WO2008074803A8 (en) 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
WO2011012246A8 (en) 4-(3-alkylthiobenzoyl)pyrazoles and use thereof as herbicides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08848850

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08848850

Country of ref document: EP

Kind code of ref document: A2